Deficiência de piruvato quinase
Revisado por Dr Adrian Bonsall, MBBSÚltima atualização por Dr Hayley Willacy, FRCGP Last updated 19 Aug 2011
Atende aos diretrizes editoriais
- BaixarBaixar
- Compartilhar
- Language
- Discussão
- Versão em Áudio
- Add to preferred sources on Google
Esta página foi arquivada.
Não foi revisado recentemente e não está atualizado. Links externos e referências podem não funcionar mais.
Profissionais de Saúde
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our artigos de saúde more useful.
Neste artigo:
Pyruvate kinase deficiency (PKD) is the most common enzyme abnormality of the glycolytic pathway. As with other hereditary red cell defects, malarial resistance is found in patients with PKD.1
Continue lendo abaixo
Patogênese
Pyruvate kinase deficiency (PKD) is a defect in the Embden-Meyerhof pathway of anaerobic glycolysis. Pyruvate kinase (PK) catalyses the conversion of phosphoenolpyruvate to pyruvate. This is one of two glycolytic reactions in the red cell that produce adenosine triphosphate (ATP).
The mismatch between the red cell's energy requirements and its ATP-generating capacity damages the membrane irreversibly, distorting and dehydrating the cell and affecting the rigidity. As a damaged cell, it is destroyed prematurely by the spleen and liver.
The low levels of ATP then have a sequential effect on intracellular electrolyte concentration as ATP powers the cation pump.
Intermediates proximal to the PK defect influence erythrocyte function. Increases in 2,3-diphosphoglycerate (2,3-DPG) levels result in a right shift in the haemoglobin-oxygen dissociation curve. This means that affected individuals have an increased capacity to release oxygen into the tissues, enhancing oxygen delivery.2
Epidemiologia
Voltar ao conteúdoPyruvate kinase deficiency (PKD) occurs worldwide but most cases have been reported in northern Europe, Japan and the USA. Many cases are found in the Amish population of Pennsylvania.
The prevalence is estimated at 51 cases per million by gene frequency studies but the observed prevalence in one northern England region was found to be 3.3 cases per million.3
Fatores de risco
Family history consistent with autosomal recessive inheritance.4 More than 150 different causative mutations have been identified.2
Although inheritance is clinically autosomal recessive, most affected individuals are compound heterozygous for two different mutant alleles.5
Acquired PKD may occur as a result of acute leukaemia, pre-leukaemia or refractory sideroblastic anaemia.
Chemotherapy may cause a more common and milder form of PKD.
Continue lendo abaixo
Apresentação
Voltar ao conteúdoThe resulting anemia hemolítica may vary from a very mild, fully compensated form, to life-threatening neonatal anaemia requiring exchange transfusion:5
Milder forms may be unnoticed until some physiological stress is experienced, eg pregnancy or viral infection, later in life. Children may have signs of anaemia, growth delay and falha no desenvolvimento.
The majority of cases are found during childhood, but some who are mildly affected may not be detected until late adulthood:
Cálculos biliares occasionally present in childhood, but usually after the first decade of life. There may be right upper quadrant tenderness and mild-to-moderate esplenomegalia.
Adults may have chronic leg ulcers.
Diagnóstico diferencial
Voltar ao conteúdo
Outros causes of haemolytic anaemia.Continue lendo abaixo
Investigações
Voltar ao conteúdoHaemoglobin concentration varies with severity of deficiency:
Anaemia is normochromic and macrocytic.
Reticulocyte count is increased by 5-15%.
Leukocyte and platelet counts may be slightly increased.
Blood film shows features of accelerated erythropoiesis, eg nucleated red blood cells. Erythrocyte lifespan is moderately-to-severely reduced.
Haemoglobin electrophoresis and red cell osmotic fragility are normal.
Indirect hyperbilirubinaemia reflects the severity of the haemolytic process. Bilirubin levels of 100 μmol/L are not uncommon and may be much higher.
The precise diagnosis depends on detecting the deficient enzyme. Measurement of the intermediate products in the pathway (2,3-DPG and glucose-6-phosphate) help confirm the diagnosis.
Gestão
Voltar ao conteúdo
This is usually supportive in mild-to-moderate cases:For neonates, therapy is focused on the treatment of anaemia and hyperbilirubinaemia.
Red blood cell transfusion may be necessary if the haemoglobin value falls significantly.
Some transfusion-dependent patients have benefited from esplenectomia. This procedure may reduce anaemia (but does not improve mild anaemia), but haemolysis will continue.6
Bone marrow transplant has been successful.7
Complicações
Voltar ao conteúdoGallstones and biliary tract obstruction may occur.
Bacterial sepsis (post-splenectomy).
Sobrecarga de ferro (from many transfusions).
Prognóstico
Voltar ao conteúdo
Morbidity and mortality correlate with disease severity and are usually the result of complications.
Hidropisia fetal can occur but generally pregnancy outcomes are good, despite sometimes severe declines in haemoglobin during pregnancy.8Prevenção
Voltar ao conteúdoDNA analysis is limited because of the large number of possible gene mutations. It is of greater value when the mutation is known.
Prenatal enzyme testing is not useful because a large amount of fetal blood is required and the test has a high rate of false-negative results.9
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Política de Privacidade. Você pode cancelar a inscrição a qualquer momento. Nunca vendemos seus dados.
Leitura adicional e referências
- Durand PM, Coetzer TL; Hereditary red cell disorders and malaria resistance. Haematologica. 2008 Jul;93(7):961-3.
- Zanella A, Fermo E, Bianchi P, et al; Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol. 2005 Jul;130(1):11-25.
- Carey PJ, Chandler J, Hendrick A, et al; Prevalence of pyruvate kinase deficiency in northern European population in the north of England. Northern Region Haematologists Group. Blood. 2000 Dec 1;96(12):4005-6.
- Pyruvate Kinase Deficiency, Online Mendelian Inheritance in Man (OMIM)
- Zanella A, Fermo E, Bianchi P, et al; Pyruvate kinase deficiency: the genotype-phenotype association. Blood Rev. 2007 Jul;21(4):217-31. Epub 2007 Mar 13.
- Steiner LA, Gallagher PG; Erythrocyte disorders in the perinatal period. Semin Perinatol. 2007 Aug;31(4):254-61.
- Tanphaichitr VS, Suvatte V, Issaragrisil S, et al; Successful bone marrow transplantation in a child with red blood cell pyruvate kinase deficiency. Bone Marrow Transplant. 2000 Sep;26(6):689-90.
- Wax JR, Pinette MG, Cartin A, et al; Pyruvate kinase deficiency complicating pregnancy. Obstet Gynecol. 2007 Feb;109(2 Pt2):553-5.
- Frye RE et al; Pyruvate Kinase Deficiency, Medscape, Dec 2008
Continue lendo abaixo
About the authorView full bio

Dr Hayley Willacy, FRCGP
Médico Generalista, Autor Médico
MBChB (1992), DRCOG, DFFP, MRCOG (Part 1) MRCGP (2007), DFSRH (2013), MSc - medical education (2020)
Dr Hayley Willacy was an NHS GP working in northwest England, who retired from clinical practice in 2022 after 30 years.
About the reviewerView full bio

Dr Adrian Bonsall, MBBS
Autor Médico
MA (Química), MBBS (Hons), DCH
Desde 2000, Adrian trabalha em pediatria de emergência e cuidados críticos em Sydney, com interesses particulares em toxicologia, trauma e ressuscitação.
Histórico do artigo
As informações nesta página são escritas e revisadas por clínicos qualificados.
19 Aug 2011 | Última versão

Pergunte, compartilhe, conecte-se.
Navegue por discussões, faça perguntas e compartilhe experiências em centenas de tópicos de saúde.

Sentindo-se mal?
Avalie seus sintomas online gratuitamente